

SUCCESS STORY



www.bioalberta.com

www.xortx.com

XORTX is a late-stage clinical pharmaceutical company dedicated to developing and commercializing innovative therapies to improve the quality of life of patients with progressive kidney disease.

XORTX's expertise and understanding of the pathological effects of aberrant purine metabolism combined with their understanding of uric acid lowering agent structure and function, has enabled the development of their proprietary therapeutic platforms, making them stand out from the rest of the field. These developments are a complementary suite of therapeutic formulations and new chemical entities designed to provide unique solutions for acute and chronic disease. Importantly, the therapeutic platforms can be used alone, or in combination, with synergistic activity to develop a multifunctional tailored approach to a variety of indications that can address disease in multiple body systems through management of chronic or acute hyperuricemia, immune modulation, and metabolic disease. XORTX continues to leverage these therapeutic platforms to expand their pipeline of novel and next generation drug-based product candidates that they believe could represent significant improvements to the standard of care in multiple acute and chronic cardiovascular diseases and specifically kidney disease.



Amanda Assen

Amanda Assen, a Master of Biomedical Technology student at the University of Calgary, interned at XORTX as her final practicum. She wanted to take the lessons she learned during her academic terms, namely combining the science and business aspects of the biotechnology sector, and put them into practice before she graduated. She has special interest in clinical research, regulatory affairs, and intellectual property and a position as a Research and Development Intern allowed her to experience it all.

During Amanda's time with XORTX, she researched and evaluated potential new strategic partners in the life science sector, researched, analyzed, and updated the comprehensive Business Development plan for a key drug development program, developed newly revised Business Plan Charter, conducted patent background research, and also started working on outlining a clinical and regulatory development plan. XORTX kept Amanda very busy over the summer, and in turn, she takes the lessons she learned there and hopes to apply them to her long-term career.

XORTX is a supporter of student learning, noting that it brings skilled talent and bright minds to the company and helps to move projects forward, at the same time providing students with valuable practical real-world experience in the life sciences field. Allen Davidoff, President and CEO of XORTX, makes a point to say that “WIL funding through BioAlberta provided a flexible and cost-effective way to hire students who always bring new and fresh ideas to our workplace. At XORTX, we are dedicated to advancing treatments that improve the care and quality of life of patients suffering from life-threatening diseases.” Student perspectives remain an important part of the ever evolving and developing life sciences industry in Alberta.

Did you know?

XORTX is the exclusive licensee of two U.S. granted patents with claims to the use of all uric acid lowering agents to treat insulin resistance or diabetic nephropathy, and two U.S. patent applications with similar claims for the treatment of metabolic syndrome, diabetes, and fatty liver disease. Counterparts for some of these patent applications have also been submitted in Europe. In both the US and Europe, XORTX owns composition of matter patent applications for unique proprietary formulations of xanthine oxidase inhibitors – U.S. and European patents have been granted. XORTX has also submitted two patent applications to cover the use of uric acid lowering agents for the treatment of the health consequences of respiratory virus infection.

WIL VOUCHER

Alberta

bio
alberta
Association for Life Sciences Industry